Immune checkpoint inhibitors, a relatively new class of anticancer therapeutics that function by blocking mechanisms of T cell inhibition frequently found in cancer, were also shown to have enhanced efficacy when combined with RON inhibition [26]. Here, MST1R is linked to cancer.